MHRA Launches Programme to Address Evidence Gaps in Women's Healthcare
The Medicines and Healthcare products Regulatory Agency launched a new Women's Health Programme on 16 November 2026 to tackle gaps in research on how medicines and medical devices affect women. Although women make up 51% of the UK population, an agency analysis of 4,616 clinical trial applications submitted between 2019 and 2023 showed that pregnant women were included in just 1.1% of trials, while breastfeeding women appeared in only 0.6%. The new initiative aims to encourage researchers to include more women in clinical trials from early design stages and to help bring new healthcare products to market faster. For ordinary readers, this focus means future treatments, medical devices, and self-care options may provide clearer evidence regarding safety, benefits, and risks specific to female biology. The agency will host an introductory webinar on 9 December to detail its plans further.
What was announced
On 16 November 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) launched its Women's Health Programme during the DIA-MHRA Global Summit in London. The announcement builds on an agency review of 4,616 UK clinical trial applications received from 2019 to 2023. That review revealed low inclusion rates for specific groups of women. Pregnant participants featured in 1.1% of trials, and breastfeeding participants appeared in 0.6%.
The programme forms part of the MHRA's 2030 Strategy to target health inequalities. It aligns with the UK government's renewed Women's Health Strategy for England and related work across Scotland, Wales, and Northern Ireland. Alongside the programme, the MHRA points to joint guidance published with the Health Research Authority. This guidance gives researchers an Inclusion and Diversity Plan framework to ensure trials better reflect the wider population.
What it means
Biological differences, age, and pregnancy can change how a person responds to medical treatments. Historically, clinical research has lacked sufficient data on female health. By pushing for trial participants to reflect the broader population, the MHRA wants to make sure new medicines and devices are tested for female biology early in development.
Better evidence can help regulatory decisions, including reclassifying medicines so patients can access them directly. For example, recent reclassifications of low-dose Estradiol vaginal products and Estriol cream broadened access to Hormone Replacement Therapy. The MHRA also noted that the UK's FemTech sector generates nearly £300 million annually. Early regulatory involvement aims to bring products to market faster.
What the announcement does not tell us
The release does not outline specific funding figures or dedicated budget amounts for the Women's Health Programme. It does not set target percentages or dates for increasing female participation in clinical trials.
The document does not detail how the MHRA will enforce the Inclusion and Diversity Plan guidance or whether compliance will be mandatory for trial approval. Finally, the announcement does not specify which exact medical conditions or device categories the agency will prioritize first. The MHRA has scheduled a public webinar for 9 December 2026, which may clarify some of these operational details.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is gov.uk: Medicines and Healthcare products Regulatory Agency’s own. Always check the original before acting on anything here.
Women’s Health Programme aims to support innovation in women’s health and better understand how the risks and benefits of medicines and medical devices may differ for women.
Opens www.gov.uk
More from gov.uk: Medicines and Healthcare products Regulatory Agency
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.